



Evolysse™ / Estyme® Filler Update

Dr. Rui Avelar, MD

Chief Medical Officer and Head of R&D

DISCLOSURES

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position; business strategy; the market growth for our product; our ability to meet our goals related to the market position of our product and product candidates; the potential market acceptance, demand market size, adoption rate, revenue expectations, future results of our product, product candidates and related loyalty programs, and timing and results of the company's clinical programs, regulatory programs and product approvals, the potential performance profile of any product candidate, are forward-looking statements. Forward-looking statements are based on current estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Other factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include uncertainties associated with the success of the launch of Jeuveau, customer and consumer adoption of the product, competition and market dynamics, the effects of economic conditions on consumer discretionary spend, the efficiency and operability of our digital platform, the ability to successfully complete clinical programs, make regulatory filings and achieve FDA approval for Evolysse and "extra strength" Jeuveau and ultimate commercial acceptability and pricing for Evolysse or a "extra strength" Jeuveau dose, our ability to comply with our settlement agreement with Medytox, and our ability to maintain regulatory approval of Jeuveau and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023 that was filed with the Securities and Exchange Commission and any subsequent filings, each of which is available online at www.sec.gov.

All written and verbal forward-looking statements attributable to our Company or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. We may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. The forward-looking statements in this presentation represent our views as of the date of this presentation. We anticipate that subsequent events and developments will cause our views to change. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances, or otherwise. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this presentation.

Certain of the industry, statistical and market data in this presentation was obtained from our own internal estimates and research as well as from industry and general publications and research, surveys and studies conducted by third parties. All of the market data used in this presentation involves a number of assumptions and limitations. While we believe that the information from these industry publications, surveys and studies is reliable, the industry in which we operate is subject to a high degree of uncertainty and risk due to a variety of important factors, which could cause results to differ materially from those expressed in the estimates made by third parties and by us. Evolus, Jeuveau, Nuceiva, Evolux and Evolysse are five of our trademarks that are used in this presentation. All other trademarks and tradenames are the property of their respective owners.

Evolysse™ Manufacturing

FIRST-GENERATION COLD TECHNOLOGY HA BY SYMATESE

CROSS-LINKING HA


Typical cross-linking: **Heat**

Symatese cross-linking: **Cold**

BENEFIT

- Cross-linking technology that better preserves the hyaluronic acid chain designed for dynamic performance and efficacy
- Potentially improves safety and efficacy for the benefit of both practitioner and patient
- Less BDDE is required to get the same gel dynamics

COLD TECHNOLOGY



European Nasolabial Study: Evolysse™ /Estyme® LIFT

STUDY DESIGN

Double blind, randomized, active control


Split face; Lift vs. Restylane-L

N=45


Duration 9 months

INJECTED VOLUMES	LIFT	RESTYLANE-L
Vol	Mean: 0.93mL	Mean: 0.95mL
Min, Max	0.30mL; 2.00mL	0.30mL; 2.00mL

PRIMARY ENDPOINT: NONINFERIORITY MEAN GRADE CHANGE IN NASOLABIAL SEVERITY SCORE




MEAN GRADE CHANGE IN NASOLABIAL SEVERITY SCORE





* Statistically significant

European Nasolabial Study: Evolysse™ /Estyme® LIFT

NASOLABIAL SEVERITY



GLOBAL AESTHETIC IMPROVEMENT



BASELINE

1 MONTH

3 MONTHS

9 MONTHS

European Perioral Fine Line Study: Evolysse™ /Estyme® SMOOTH

STUDY DESIGN


Prospective, single arm, no control, multi-center

N=61

Duration 12 months

Average volume injected: 0.5mL

- No touch ups



European Mid Face Volume Study: Evolysse™ / Estyme® SCULPT


STUDY DESIGN

Prospective, no control, single center

N=60

Duration 18 months

3D CHEEK VOLUMETRIC CHANGE FROM BASELINE (mL)



VOLUME INJECTED	SCULPT: RIGHT CHEEK	SCULPT: LEFT CHEEK
Mean Vol	Mean: 0.93mL	Mean: 0.95mL

European Lips Study: Evolysse™ /Estyme® LIPS


STUDY DESIGN

Prospective, single arm, multi-center

N=72 patients

Duration 12 months

MEAN GRADE CHANGE FROM BASELINE IN LIP FULLNESS




	LIPS	EMERVEL LIPS/ RESTYLANE KYSSE
INCLUSION	72 (93.3% female)	44 (95.5% female)
MEAN AGE	55.7 yrs	54.5 yrs
PRODUCT VOLUMES		
INITIAL TREATMENT	1.0±0.6mL	1.0±0.4mL
TOUCH UP TREATMENT	Not allowed	0.7±0.3mL
MEAN TOTAL	1.0±0.6mL	1.3±0.6mL

Note: Results drawn from multiple studies. Caution should be used when interpreting cross-study comparisons
Source: *Journal of Drugs in Dermatology*, "Emervel®: Full-Face Rejuvenation With a Range of Customized hyaluronic Acid Fillers", January 2012, v11, Issue 1(Supplement)

European Lips Study: Evolysse™ /Estyme® LIPS

GLOBAL AESTHETIC SCORE



BASELINE



DAY 30



MONTH 6



MONTH 12

Portfolio of Brands

JEUVEAU®

- PrabotulinumtoxinA-xvfs injection

EVOLYSSE™

US 5 Indications

- 2 in 2025 (Smooth, Lift)¹
- 1 in 2026 (Sculpt)¹
- 2 in 2027 (Eyes, Lips)¹

ESTYME®

EU 5 Indications in 2H 2024²

- Smooth (NLF, Perioral Fine Lines)
- Lift (NLF)
- Sculpt (Mid Face Volume)
- Lips (Lip Volume)

1. Expected launches subject to prior FDA approval
2. Expected launches subject to prior EU approval

Jeuveau® 
prabotulinumtoxinA-xvfs injection byevolus



EVOLYSSE™ 
byevolus

